Key result
A survey of 202 European cardiologists and electrophysiologists found that beta-blockers and class I antiarrhythmic drugs are the preferred pharmacological option for idiopathic monomorphic PVCs (81%).
Why the study?
Trends in the clinical management of idiopathic monomorphic premature ventricular contractions among European cardiologists and cardiac electrophysiologists needed to be understood.
Cross-Sectional (n=202)
Yes
European cardiologists and electrophysiologists prefer beta-blockers, class I antiarrhythmics, and catheter ablation for managing idiopathic monomorphic PVCs, relying heavily on 24-h Holter monitoring for assessment.
Documents prevailing European practice patterns for idiopathic PVCs; leaves open need for RCTs on optimal therapy.
On behalf of the European Heart Rhythm Association, we designed a survey, whose aim was to understand the trend(s) in the clinical management of idiopathic monomorphic premature ventricular contractions (PVCs) among European cardiologists and cardiac electrophysiologists. A total of 202 participants in the survey answered 27 multiple-choice questions on the clinical presentation, diagnosis and treatment of idiopathic monomorphic PVCs. The most common symptom in patients with idiopathic monomorphic PVCs is palpitations, according to the majority of responders (87%), followed by fatigue (29%) and dizziness (18%). Complete blood cell count, renal function with electrolytes levels, and thyroid function are the blood tests requested by the majority of respondents (65%, 92%, and 93%, respectively). Coronary artery disease and structural heart disease needs to be ruled out, according to the vast majority of participants (99%). A 24-h Holter ECG is the preferred ECG modality to assess the burden of PVCs (86% of respondents). Among the different option treatments, beta-blockers and class I antiarrhythmic drugs are by far (81% of respondents) the preferred pharmacological option in comparison with calcium antagonists and class III antiarrhythmic drugs. Catheter ablation has also a good reputation: 99% of responders are keen to use it, especially in patients with high burden of PVCs and when signs of cardiomyopathy occur.
No takes yet. Share an insight, caveat, or question.
Sorgente et al. (2022) conducted a cross-sectional in Idiopathic monomorphic premature ventricular contractions (PVCs) (n=202). Survey on clinical management practices was evaluated on Survey responses regarding clinical presentation, diagnosis, and treatment. A survey of 202 European cardiologists and electrophysiologists found that beta-blockers and class I antiarrhythmic drugs are the preferred pharmacological option for idiopathic monomorphic PVCs (81%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: